DOSA2, as the latest phase is known, is coordinated by the University of Edinburgh and includes partners at the University of the Arts London, Silchar Medical College, Assam University and the IIT Delhi. "Through our work, we hope to help slow the emergence of drug-resistant infections and improve the ability to diagnose and treat them," said Dr Mike Strange, Head of Global Health, LifeArc.
Thursday 22 June 202312:00-13:30 (CEST) BackgroundThe global research agenda for AMR in human health aims to catalyze research on the burden and impact of AMR, strategies to prevent infections and development of resistance, the discovery and development of new diagnostics and better treatment regimens, and how to optimize the use of current tools and implement them more efficiently. Ultimately, it aims to inform evidence-based policies and interventions to strengthen the AMR response, especially in low-and-middle-income countries (LMICs).The research agenda was developed following a rigorous and transparent process starting with a scoping review of over 3,000 documents in the past 10 years which generated 2,340 knowledge gaps. Following several rounds of review and consolidation of these knowledge gaps into research questions, over 230 experts globally across a range of disciplines related to AMR research scored the questions against five criteria in a transparent, independent and r